S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
Biden's Plan to Confiscate Your Cash? (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
Biden's Plan to Confiscate Your Cash? (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
Biden's Plan to Confiscate Your Cash? (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
Biden's Plan to Confiscate Your Cash? (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Biden's Plan to Confiscate Your Cash? (Ad)
NASDAQ:RUBY

Rubius Therapeutics - RUBY Stock Forecast, Price & News

$0.80
+0.04 (+5.26%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.75
$0.81
50-Day Range
$0.65
$1.24
52-Week Range
$0.65
$24.84
Volume
254,996 shs
Average Volume
395,736 shs
Market Capitalization
$72.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Rubius Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
525.1% Upside
$5.00 Price Target
Short Interest
Bearish
8.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
0.76mentions of Rubius Therapeutics in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$4,590 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.91) to ($1.65) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.57 out of 5 stars

Medical Sector

181st out of 1,135 stocks

Biological Products, Except Diagnostic Industry

31st out of 180 stocks

RUBY stock logo

About Rubius Therapeutics (NASDAQ:RUBY) Stock

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Analyst Upgrades and Downgrades

Separately, HC Wainwright lowered their price objective on Rubius Therapeutics from $15.00 to $8.00 in a research report on Wednesday, May 11th.

Rubius Therapeutics Stock Up 5.5 %

Rubius Therapeutics stock traded up $0.04 during mid-day trading on Friday, hitting $0.80. The company's stock had a trading volume of 254,996 shares, compared to its average volume of 395,736. Rubius Therapeutics has a 1 year low of $0.65 and a 1 year high of $24.84. The stock's fifty day moving average is $0.86 and its two-hundred day moving average is $2.72. The company has a current ratio of 4.63, a quick ratio of 6.23 and a debt-to-equity ratio of 0.80.

Receive RUBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rubius Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RUBY Stock News Headlines

Rubius Therapeutics Inc - Stock News
What 6 Analyst Ratings Have To Say About Rubius Therapeutics
Rubius Therapeutics up 34% after insider buy
Expert Ratings for Rubius Therapeutics
See More Headlines
Receive RUBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rubius Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

RUBY Company Calendar

Last Earnings
11/08/2021
Today
8/14/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RUBY
Fax
N/A
Employees
269
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+525.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-196,550,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.06 per share

Miscellaneous

Free Float
42,649,000
Market Cap
$72.28 million
Optionable
Not Optionable
Beta
2.60

Key Executives














RUBY Stock - Frequently Asked Questions

Should I buy or sell Rubius Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RUBY shares.
View RUBY analyst ratings
or view top-rated stocks.

What is Rubius Therapeutics' stock price forecast for 2022?

4 equities research analysts have issued twelve-month price objectives for Rubius Therapeutics' shares. Their RUBY share price forecasts range from $3.00 to $8.00. On average, they expect the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 525.1% from the stock's current price.
View analysts price targets for RUBY
or view top-rated stocks among Wall Street analysts.

How have RUBY shares performed in 2022?

Rubius Therapeutics' stock was trading at $9.68 at the beginning of the year. Since then, RUBY shares have decreased by 91.7% and is now trading at $0.7999.
View the best growth stocks for 2022 here
.

When is Rubius Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our RUBY earnings forecast
.

How were Rubius Therapeutics' earnings last quarter?

Rubius Therapeutics, Inc. (NASDAQ:RUBY) announced its earnings results on Monday, November, 8th. The company reported ($0.55) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.01. During the same period in the prior year, the company posted ($0.51) earnings per share.

What is Pablo Cagnoni's approval rating as Rubius Therapeutics' CEO?

12 employees have rated Rubius Therapeutics Chief Executive Officer Pablo Cagnoni on Glassdoor.com. Pablo Cagnoni has an approval rating of 91% among the company's employees. This puts Pablo Cagnoni in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Rubius Therapeutics own?

When did Rubius Therapeutics IPO?

(RUBY) raised $200 million in an initial public offering on Wednesday, July 18th 2018. The company issued 9,500,000 shares at a price of $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners acted as the underwriters for the IPO.

What is Rubius Therapeutics' stock symbol?

Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."

Who are Rubius Therapeutics' major shareholders?

Rubius Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.92%), State of Michigan Retirement System (0.73%), JPMorgan Chase & Co. (0.62%), Connor Clark & Lunn Investment Management Ltd. (0.39%), Northern Trust Corp (0.08%) and LPL Financial LLC (0.07%). Insiders that own company stock include Christina M Coughlin, Christopher L Carpenter, Dannielle Appelhans, David R Epstein, Maiken Keson-Brookes, Pablo J Cagnoni, Robert Langer and Ventures Fund Iv Gene Flagship.
View institutional ownership trends
.

How do I buy shares of Rubius Therapeutics?

Shares of RUBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rubius Therapeutics' stock price today?

One share of RUBY stock can currently be purchased for approximately $0.80.

How much money does Rubius Therapeutics make?

Rubius Therapeutics (NASDAQ:RUBY) has a market capitalization of $72.28 million. The company earns $-196,550,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis.

How many employees does Rubius Therapeutics have?

The company employs 269 workers across the globe.

How can I contact Rubius Therapeutics?

Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The official website for the company is www.rubiustx.com. The company can be reached via phone at (617) 679-9600 or via email at ir@rubiustx.com.

This page (NASDAQ:RUBY) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.